Preliminary clinical benefit information is translated into longer-term health benefit and economic value through pricing models, making them invaluable for decision-making. In the era of COVID-19 it is difficult to rely on a single pricing model without some guides to assess applicability. Institute for Clinical and Economic Review (ICER) presents the pros and cons of a number of pricing models and suggests three crucial areas that must be considered in choice of model and interpretation of results: target population, disease management goals, and policy objectives. Read the full paper here.
(Source: Chou J J Clin Pathways. 2020;6(6):23-25)